Urszula Ambroziak

Dr. Urszula Ambroziak


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
APAlessandro Prete
Alessandro Prete
ASAnuradhaa Subramanian
Anuradhaa Subramanian
IBIrina Bancos
Irina Bancos
VCVasileios Chortis
Vasileios Chortis
STStylianos Tsagarakis
Stylianos Tsagarakis
EIENSAT EURINE-ACT Investigators*
ENSAT EURINE-ACT Investigators*
Benign adrenal tumors are commonly discovered on cross-sectional imaging that is done for other reasons. This study examined whether the mild autonomous cortisol secretion often found with these tu... Visual Cardiometabolic Disease Burden in Benign Adrenal Tumors. Benign adrenal tumors are commonly discovered on cross-sectional imaging that is done for other reasons. This study examined... Background: Benign adrenal tumors are commonly discovered on cross-sectional imaging. Mild autonomous cortisol secretion (MACS) is regularly diagnosed, but its effect on cardiometabolic disease in ...

1 December 2017 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Closed access
UAUrszula Ambroziak
Urszula Ambroziak
SHSandra Hybsier
Sandra Hybsier
USUrszula Shahnazaryan
Urszula Shahnazaryan
MKMałgorzata Krasnodębska-Kiljańska
Małgorzata Krasnodębska-Kiljańska
EREddy Rijntjes
Eddy Rijntjes
Lutz SchomburgLutz Schomburg
Lutz Schomburg

15 July 2015 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
UAUrszula Ambroziak
Urszula Ambroziak
AKAgnieszka Kondracka
Agnieszka Kondracka
ZBZbigniew Bartoszewicz
Zbigniew Bartoszewicz
MKMałgorzata Krasnodębska‐Kiljańska
Małgorzata Krasnodębska‐Kiljańska
TBTomasz Bednarczuk
Tomasz Bednarczuk

22 November 2017 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
KMKlaudia Malec
Klaudia Malec
PMPiotr Miśkiewicz
Piotr Miśkiewicz
Agnieszka Witkowska-JanikAgnieszka Witkowska-Janik
Agnieszka Witkowska-Janik
EKEwa Krajewska
Ewa Krajewska
STSadegh Toutounchi
Sadegh Toutounchi
UAUrszula Ambroziak
Urszula Ambroziak
Background: Adrenalectomy with preoperative pharmacological preparation is strongly recommended in patients diagnosed with pheochromocytoma, in order to prevent perioperative complications. Aim: To compare phenoxybenzamine (PhB) and doxazosin (DOX) in terms of perioperative haemodynamic status in patients with pheochromocytoma, who have been prepared for adrenalectomy. Methods: Retrospective analysis of 44 patients with pheochromocytoma (aged 16–80 years, 29 females) who underwent adrenalectomy. Patients were divided into two groups: 35 patients on DOX and nine patients on PhB. Results: Mean time of preparation for surgery was 38.8 days in the DOX group and 18.3 days in the PhB group (p = 0.04). No statistically significant differences between the DOX and PhB groups in intraoperative blood pressure (BP) fluctuations were found: < 170/100 mm Hg (34% vs. 44%, respectively, p = 0.42), ≥ 200/110 mm Hg (40% vs. 22%, respectively, p = 0.28). Mean greatest intraoperative systolic BP (195 ± 53 vs. 166 ± 42 mm Hg, p = 0.21) and diastolic BP (98 ± 20 vs. 89 ± 46 mm Hg, p = 0.21), and mean lowest intraoperative systolic BP (87 ± 13 vs. 79 ± 17 mm Hg, p = 0.25) and diastolic BP (49 ± 8 vs. 46 ± 12 mm Hg, p = 0.60) were not different between the DOX and PhB groups, respectively. Sodium nitroprusside was administrated in 30% DOX vs. 11% PhB patients (p = 0.25). Laparoscopic surgery was conducted in 97% DOX vs. 89% PhB patients (p = 0.64). Postoperative BP drop below 90/60 mm Hg was noted in 48% of the DOX vs. 43% of the PhB group (p = 0.56). Negative correlation was found between the length of DOX administration with maximal intraoperative systolic BP (r = –0.45, p = 0.006) and diastolic BP (r = –0.39, p = 0.019). Conclusions: There are no clinically relevant differences between patients with pheochromocytoma, who have been prepared for adrenalectomy with DOX or PhB. Background: Adrenalectomy with preoperative pharmacological preparation is strongly recommended in patients diagnosed with pheochromocytoma, in order to prevent perioperative complications. Aim: To compare phenoxybenzamine (PhB) and doxazosin (DOX) in terms of perioperative haemodynamic status in patients with pheochromocytoma, who have been prepared for adrenalectomy. Methods: Retrospective analysis of 44 patients with pheochromocytoma (aged 16–80 years, 29 females) who underwent adrenalectomy. Patients were divided into two groups: 35 patients on DOX and nine patients on PhB. Results: Mean time of preparation for surgery was 38.8 days in the DOX group and 18.3 days in the PhB group (p = 0.04). No statistically significant differences between the DOX and PhB groups in intraoperative blood pressure (BP) fluctuations were found: < 170/100 mm Hg (34% vs. 44%, respectively, p = 0.42), ≥ 200/110 mm Hg (40% vs. 22%, respectively, p = 0.28). Mean greatest intraoperative systolic BP (195 ± 53 vs. 166 ± 42 mm Hg, p = 0.21) and diastolic BP (98 ± 20 vs. 89 ± 46 mm Hg, p = 0.21), and mean lowest intraoperative systolic BP (87 ± 13 vs. 79 ± 17 mm Hg, p = 0.25) and diastolic BP (49 ± 8 vs. 46 ± 12 mm Hg, p = 0.60) were not different between the DOX and PhB groups, respectively. Sodium nitroprusside was administrated in 30% DOX vs. 11% PhB patients (p = 0.25). Laparoscopic surgery was conducted in 97% DOX vs. 89% PhB patients (p = 0.64). Postoperative BP drop below 90/60 mm Hg was noted in 48% of the DOX vs. 43% of the PhB group (p = 0.56). Negative correlation was found between the length of DOX administration with maximal intraoperative systolic BP (r = –0.45, p = 0.006) and diastolic BP (r = –0.39, p = 0.019). Conclusions: There are no clinically relevant differences between patients with pheochromocytoma, who have been prepared for adrenalectomy with DOX or PhB.

14 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
JBJoanna Betlejewska
Joanna Betlejewska
JHJoanna Hubska
Joanna Hubska
ZRZuzanna Roszkowska
Zuzanna Roszkowska
AMAleksandra Maciejczyk
Aleksandra Maciejczyk
DBDominika Bachurska
Dominika Bachurska
UAUrszula Ambroziak
Urszula Ambroziak
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the hepatic manifestation of systemic metabolic dysregulation, strongly linked to type 2 diabetes, cardiovascular diseases, liver-related complications, and different types of malignancies. Although MASLD is associated with obesity and insulin resistance, it is increasingly recognized that the liver engages in complex crosstalk with several endocrine pathways, including thyroid function, sex and steroid hormone regulation, and growth hormone signaling. The pathophysiology of MASLD is multifactorial and complex, as reflected by its clinical range—from simple steatosis to cirrhosis. MASLD now affects about one-quarter of the global population, with its prevalence rising due to sedentary lifestyles, chronic caloric excess, and endocrine disturbances contributing to disease progression. Given the escalating prevalence of MASLD and its frequent concurrence with various endocrinopathies, understanding this relationship is critical for refining diagnostic accuracy and optimizing therapeutic strategies. This review aims to synthesize contemporary insights into the complex interactions between MASLD and selected endocrine disorders, elucidate underlying pathophysiological mechanisms, and underscore novel treatment paradigms. As MASLD remains a significant clinical challenge worldwide, its intersection with endocrine dysfunctions represents a vital and promising domain for future research and clinical management.

14 March 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
PMPaweł Matryba
Paweł Matryba
KGKarol Gawalski
Karol Gawalski
ICIga Ciesielska
Iga Ciesielska
AHAndrea Horvath
Andrea Horvath
ZBZbigniew Piotr Bartoszewicz
Zbigniew Piotr Bartoszewicz
RKRafal Krenke
Rafal Krenke
An increasing body of evidence from both academic and clinical studies shows that time-of-day exposure to antigens might significantly alter and modulate the development of adaptive immune responses. Considering the immense impact of the COVID-19 pandemic on global health and the diminished efficacy of vaccination in selected populations, such as older and immunocompromised patients, it is critical to search for the most optimal conditions for mounting immune responses against SARS-CoV-2. Hence, we conducted an observational study on 435 healthy young adults vaccinated with two doses of BNT162b2 (Pfizer-BioNTech) vaccine to determine whether time-of-day of vaccination influences either the magnitude of humoral response or number of adverse drug reactions (ADR) being reported. We found no significant differences between morning and afternoon vaccination in terms of both titers of anti-Spike antibodies and frequency of ADR in the studied population. In addition, our analysis of data on the occurrence of ADR in 1324 subjects demonstrated that the second administration of vaccine in those with previous SARS-CoV-2 infection was associated with lower incidence of ADR. In aggregate, vaccination against COVID-19 with two doses of BNT162b2 mRNA vaccine is presumed to generate an equally efficient anti-Spike humoral response.